Imaging of Vitreous Opacities in Human Eyes

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Vitreous opacities (VOs), commonly known as floaters, are dark spots that appear in, and may float across your vision. Presently, there is a lack of available data in the literature regarding VOs. This study aims to obtain imaging data of VOs in the population to build an imaging database of VOs to learn more about them.

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06204848` - Imaging of Vitreous Opacities in a Canadian Population	N/A
	Completed	`NCT02897583` - YAG Vitreolysis for Floaters	N/A

NCT number	NCT06097897
Study type	Interventional
Source	PulseMedica
Contact	Study Coordinator
Phone	+1-507-269-7475
Email	info@panamaeyecenter.com
Status	Recruiting
Phase	N/A
Start date	April 1, 2024
Completion date	September 2024

Imaging of Vitreous Opacities in Human Eyes

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms